NCT03168074: Phase II Study of Single Agent Lenvatinib

NCT03168074
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER++
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Tyrosine Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: If HER2++ or HR++/HER2-negative, must also have ER++ tumor(s)
Exclusions: Symptomatic brain metastasis
https://ClinicalTrials.gov/show/NCT03168074

Comments are closed.

Up ↑